Landmark Trials on Anesthesia Exposure and Neurodevelopmental Outcomes in Pediatric Patients
The GAS (General Anaesthesia compared to Spinal anaesthesia) trial is the landmark randomized controlled trial that definitively examined the correlation between anesthesia exposure and neurodevelopmental outcomes in pediatric patients 1, 2.
The GAS Trial: Key Design and Findings
The GAS trial was an international, multicentre, randomized, controlled equivalence trial conducted across 28 hospitals in 7 countries (Australia, Italy, USA, UK, Canada, Netherlands, and New Zealand) 1, 2. This study specifically addressed whether general anesthesia in early infancy affects neurodevelopmental outcomes by comparing:
- Intervention groups: Awake-regional anesthesia versus sevoflurane-based general anesthesia
- Population: Infants <60 weeks postmenstrual age, born >26 weeks gestation, undergoing inguinal herniorrhaphy
- Exclusion criteria: No previous anesthesia exposure or pre-existing neurological risk factors
- Sample size: 722 infants randomized (363 to awake-regional, 359 to general anesthesia)
Primary Outcome at 5 Years
The primary endpoint was full-scale intelligence quotient (FSIQ) using the Wechsler Preschool and Primary Scale of Intelligence, third edition (WPPSI-III) at age 5 years 1.
Key results:
- Mean FSIQ: 99.08 (awake-regional) vs 98.97 (general anesthesia)
- Difference in means: 0.23 (95% CI -2.59 to 3.06)
- Median duration of general anesthesia: 54 minutes
- Conclusion: Strong evidence of equivalence—less than 1 hour of sevoflurane anesthesia does not alter neurodevelopmental outcome at age 5 years
Secondary Outcome at 2 Years
At the 2-year assessment, the Bayley Scales of Infant and Toddler Development III composite cognitive score showed 2:
- Mean score: 98.6 (awake-regional) vs 98.2 (general anesthesia)
- Difference: 0.169 (95% CI -2.30 to 2.64)
- No evidence of adverse neurodevelopmental outcome at 2 years
Clinical Context and Interpretation
What This Means for Practice
The GAS trial provides the highest-quality evidence (Level 1, randomized controlled trial) that single, brief exposures to general anesthesia (<1 hour) in otherwise healthy infants do not cause measurable neurodevelopmental deficits 1, 2. This directly addresses the concerns raised by preclinical animal studies showing neuronal apoptosis and behavioral deficits after anesthetic exposure 3.
Important Caveats
The GAS trial has specific limitations that clinicians must recognize:
Duration-dependent effects: The trial only evaluated ~54 minutes of anesthesia exposure. The SmartTots guidelines note that "concerns from both preclinical and clinical studies regarding longer duration and multiple exposures remain unsettled" 3.
Single exposure only: The trial excluded children with previous anesthesia exposure, so it cannot address cumulative effects of multiple procedures 4.
Predominantly male population: The study population was primarily male (inguinal herniorrhaphy patients), which may limit generalizability 1.
Healthy infants only: Children with pre-existing neurological risk factors were excluded, so findings may not apply to critically ill or neurologically vulnerable children 2.
Ongoing Concerns
While single brief exposures appear safe, multiple or prolonged exposures remain a concern. Recent evidence suggests that multiple, prolonged exposures may be associated with dysfunctions in learning, behavior, and social communication, though confounding variables complicate interpretation 4. Additionally, sedative choice during critical illness may matter—children receiving opioid-and-benzodiazepine-only strategies scored lower on IQ testing than those receiving dexmedetomidine-inclusive regimens 5.
Practical Clinical Algorithm
For single, brief procedures (<1 hour) in healthy infants:
- Proceed with medically necessary surgery without delay
- Reassure families based on GAS trial evidence
- Document anesthesia duration
For prolonged procedures (>1 hour) or multiple exposures:
- Still proceed with medically necessary procedures (current literature does not support delay) 4
- Consider minimizing total anesthetic exposure when safely possible
- Discuss uncertainty with families regarding prolonged/multiple exposures
- Document cumulative exposure history
For critically ill children requiring sedation:
- Consider dexmedetomidine-inclusive strategies over opioid-and-benzodiazepine-only approaches 5
- Balance neurodevelopmental concerns with immediate clinical needs
The GAS trial represents the definitive human evidence addressing this question, superseding earlier cohort studies that were prone to confounding bias 1, 2.